Silver Book

Silver Book Fact

Over the past 15 years, three classes of drugs have reduced mortality and improved symptoms of heart failure in patients who have decreased heart muscle function. These classes of drugs are ACE inhibitors, beta adrenergic blocking agents, and aldosterone antagonists. They each decrease mortality per year by 10-40%, and the beneficial effects of each agent have appeared in large-scale clinical trials to be additive.

Weisfeldt M, Zeiman S. Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease. Health Aff. 2007; 26(1): 25-37. http://content.healthaffairs.org/cgi/content/full/26/1/25

Reference

Title
Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease
Publication
Health Aff
Publication Date
2007
Authors
Weisfeldt M, Zeiman S
Volume & Issue
Volume 26, Issue 1
Pages
25-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • Over the past 15 years, three classes of drugs have reduced mortality and improved symptoms of heart failure in patients who have decreased heart muscle function. These classes of drugs…  
  • Compared to standard coverage, 3 years of full coverage for prevention medications will reduce mortality and reinfarction rates and will save $5,974 per patient.  
  • Increased use of non-acute medications in primary and secondary prevention explains about 1/3 of the total reduction in cardiovascular disease mortality since 1950.